Setipiprant

Setipiprant is a potent, orally available and selective CRTH2 antagonist, which is a G protein-coupled receptor for PGD2. It may be a promising target for the treatment of allergic disorders. It was well tolerated and reduced both the allergen-induced LAR and the associated AHR in allergic asthmatics at multiple oral doses. It is a drug originally developed by Actelion, but it failed to show sufficient advantages and was discontinued from further development in this application. Later it was developed as a novel treatment for baldness by Kythera.